Calcium carbonate does not affect nilotinib pharmacokinetics in healthy volunteers

[1]  Jin Hyun Cho,et al.  Nilotinib in patients with metastatic melanoma harboring KIT gene aberration , 2012, Investigational New Drugs.

[2]  Y. Kakeji,et al.  Phase 2 study of nilotinib as third‐line therapy for patients with gastrointestinal stromal tumor , 2011, Cancer.

[3]  I. Flinn,et al.  Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. , 2011, The Lancet. Oncology.

[4]  A. Ravaud,et al.  Exposure–response relationships in patients with metastatic renal cell carcinoma receiving sunitinib: maintaining optimum efficacy in clinical practice , 2011, Anti-cancer drugs.

[5]  W. Zhou,et al.  Effect of the Proton Pump Inhibitor Esomeprazole on the Oral Absorption and Pharmacokinetics of Nilotinib , 2010, Journal of clinical pharmacology.

[6]  M. Egorin,et al.  A high-performance liquid chromatography-mass spectrometry assay for quantitation of the tyrosine kinase inhibitor nilotinib in human plasma and serum. , 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[7]  G. Demetri,et al.  Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Egorin,et al.  Effect of antacid on imatinib absorption , 2009, Cancer Chemotherapy and Pharmacology.

[9]  G. Demetri,et al.  Imatinib pharmacokinetics (PK) and its correlation with clinical response in patients with unresectable/metastatic gastrointestinal stromal tumor (GIST) , 2008 .

[10]  Tillmann Krahnke,et al.  Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. , 2008, Blood.

[11]  E. Meurer,et al.  Bio equivalence of Two Enteric Coated Formulations of Pantoprazole in Healthy Volunteers under Fasting and Fed Conditions , 2007, Arzneimittelforschung.

[12]  Deborah A. Straub.  Calcium supplementation in clinical practice: a review of forms, doses, and indications. , 2007, Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition.

[13]  Nicholas Moore,et al.  Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. , 2007, Blood.

[14]  K. Bhalla,et al.  Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. , 2006, The New England journal of medicine.

[15]  Mary Frances Picciano,et al.  Dietary supplement use by US adults: data from the National Health and Nutrition Examination Survey, 1999-2000. , 2004, American journal of epidemiology.

[16]  M. Egorin,et al.  Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma. , 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[17]  A. D. Van den Abbeele,et al.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.

[18]  R. Pazdur,et al.  Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  C. Sawyers,et al.  Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.

[20]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[21]  M. Gordon.  Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia , 2010 .